Clinical Trial Update: Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia [Phase 3]

View source ↗

Summary

LENZ Therapeutics completed a Phase 3 efficacy trial of LNZ100 and LNZ101 for presbyopia. Results were posted on 2026-02-25.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Presbyopia

Drugs mentioned

• LNZ100 (Aceclidine)
• LNZ101 (Aceclidine/Brimonidine)

Snippet

Sponsor: LENZ Therapeutics, Inc | Conditions: Presbyopia, Near Vision | Phase 3 | Status: COMPLETED | Results posted: 2026-02-25